 |
|
Blood-compatible nanoscale materials possible using heparin
May 08, 2006TROY, N.Y. - Researchers from Rensselaer Polytechnic Institute have engineered nanoscale materials that are blood compatible using heparin, an anticoagulant. The heparin biomaterials have potential for use as medical devices and in medical treatments such as kidney dialysis.
The researchers prepared several materials with heparin composites or coatings, including carbon nanotubes, nanofibers, and membranes with nanosized pores, and then demonstrated the materials' high compatibility with blood. Heparin is a common therapeutic used to maintain blood flow or prevent clotting during medical procedures and treatments.
The researchers demonstrated the composite heparin membrane with nanopores could work as an artificial kidney, or dialyzer, by filtering the blood and maintaining its flow. The presence of this blood-compatible dialyzer could potentially eliminate the need for systemic administration of heparin to the patient during kidney dialysis, the researchers say.
The heparin-coated membranes are described in a paper titled "Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis," published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.
"These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology," says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. "Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible."
The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer, and includes collaboration with Pulickel Ajayan, the Henry Burlage Professor of Materials Science and Engineering, and Omkaram "Om" Nalamasu, professor of materials science and engineering, at Rensselaer. Additional co-authors of the paper are Shaker Mousa, director of the Pharmaceutical Research Institute at Albany College of Pharmacy, and Aravind Vijayaraghavan, a recent doctoral graduate in materials science and engineering at Rensselaer. Funding for this research was provided by the National Institutes of Health.
Recent results related to this work have been published online in the journals Langmuir ("Blood Compatible Nanotubes Ã-¿½ Nano-based Neoproteoglycans," Mar. 11, 2006) and Biomacromolecules ("Preparation of Biopolymer Fibers by Electrospinning from Room Temperature Ionic Liquids," Jan. 26, 2006). Provisional patents have been filed by Rensselaer Polytechnic Institute.
Research in Linhardt's group at the Center for Biotechnology and Interdisciplinary Studies at Rensselaer focuses on complex carbohydrates such as heparin. After determining the structure of these molecules, researchers study their biological activities to establish a structure-activity relationship that may reveal lead compounds for new drug development. Recent discoveries include a synthetic method for preparation of heparin in quantities large enough for use in medical treatment.
Rensselaer Polytechnic Institute
The heparin-coated membranes are described in a paper titled "Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis," published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.
"These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology," says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. "Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible."
The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer, and includes collaboration with Pulickel Ajayan, the Henry Burlage Professor of Materials Science and Engineering, and Omkaram "Om" Nalamasu, professor of materials science and engineering, at Rensselaer. Additional co-authors of the paper are Shaker Mousa, director of the Pharmaceutical Research Institute at Albany College of Pharmacy, and Aravind Vijayaraghavan, a recent doctoral graduate in materials science and engineering at Rensselaer. Funding for this research was provided by the National Institutes of Health.
Recent results related to this work have been published online in the journals Langmuir ("Blood Compatible Nanotubes Ã-¿½ Nano-based Neoproteoglycans," Mar. 11, 2006) and Biomacromolecules ("Preparation of Biopolymer Fibers by Electrospinning from Room Temperature Ionic Liquids," Jan. 26, 2006). Provisional patents have been filed by Rensselaer Polytechnic Institute.
Research in Linhardt's group at the Center for Biotechnology and Interdisciplinary Studies at Rensselaer focuses on complex carbohydrates such as heparin. After determining the structure of these molecules, researchers study their biological activities to establish a structure-activity relationship that may reveal lead compounds for new drug development. Recent discoveries include a synthetic method for preparation of heparin in quantities large enough for use in medical treatment.
Rensselaer Polytechnic Institute
Heparin Current Events and Heparin News RSSScientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.
Investigation of contaminated heparin syringes highlights medication safety issues
An outbreak of bloodstream infections appears to have been caused by the contamination of pre-filled heparin and saline syringes made by a single company.
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes
Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).
Patient safety advanced by revised heparin standards
Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner.
'Artificial Golgi' may provide new insight into key cell structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle.
Research highlights new approaches to prevent blood clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured.
Simple new method detects contaminants in life-saving drug
The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths.
HORIZONS AMI will help set guidelines for drug and stent therapy
The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy - heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding.
Safety of antithrombotic treatment in acute coronary syndromes
The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.
More Heparin Current Events and Heparin News Articles
 |
Heparin-Induced Thrombocytopenia, Fourth Edition (Fundamental and Clinical Cardiology) by Theodore E. Warkentin (Editor), Andreas Greinacher (Editor) Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most potentially devastating and frequent adverse drug reactions encountered by physicians. This Fourth Edition reinforces its standing as the leading guide to the accurate diagnosis and management of HIT by identifying key signs and symptoms of this disorder and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage these critical circumstances. Intended for those requiring an expert source of guidance for the quick detection and control of HIT, this reference: contains new chapters on novel pharmacotherapies, recent drug approvals, current dosing guidelines, and... |
 |
Monoject Prefill I.V. Syringes - 12mL Syringe, Filled with 5mL 100U/mL Heparin Flush - 180 Per Case - Model SWD590125 by TYCO/KENDALL Saline and heparin flush syringes.Terminally sterile.Drug stopper quality plunger tip.Color-coded.Low breakforce.Latex and perservative free. |
 |
B-d Vacutainer Plus Plastic Plasma Tubes 13 X 100 4.5ml Pst Tube W/ Polymer Gel And Lithium Heparin by Becton-dickinson B-D Vacutainer Plus Plastic Plasma Tubes 13 x 100 4.5mL PST Tube w/ Polymer Gel and Lithium Heparin : BD safety-engineered plastic blood collection tubes provide not only a clinically tested alternative to traditional glass tubes, but also offer you and your staff reduced risk of tube breakage and specimen spillage, thereby reducing risk of exposure to bloodborne pathogens, and are also in compliance with OSHA standards. Sterile. |
|
Fisherbrand Micro Blood Collecting Tubes; Heparin; 100/pack by Fisher Scientific Tubes, capillary blood collection; Fisherbrand; Micro blood collecting tubes; caraway; Heparin; Red tip; 100/pack | |
|
Heparin and Related Polysaccharides: Structure and Activities (Annals of the New York Academy of Sciences) by Frederick A. Ofosu (Author), Isidore Danishefsky (Author), Jack Hirsh (Editor) | |
 |
60 Minutes - The Wrong Medicine (March 16, 2008) Airdate: 03/16/08 As many as 100,000 people die each year from medical errors, and the newborn twins of actor Dennis Quaid and his wife Kimberly were nearly part of that statistic. When only days old, the babies were accidentally given the wrong dose of the blood thinner Heparin, and they nearly bled to death. Steve Kroft talks with the couple about their ordeal and about the issue of preventable medical mistakes. |
 |
Site Selection and Injection Techniques (Parenteral Medication Administration) (Volume Four) Also With: Concept Media (Primary Contributor) Discusses common intramuscular injection sites and essential assessment considerations. Concisely describes the techniques for administration of intra-muscular medications with emphasis on the displacement or Z-track method. Subcutaneous site selection is also discussed. Procedures, including specific techniques for insulin and heparin administration, are illustrated in detail. |
|
Hate Me | |
|
Hospira Injectables/Multidose Vials - Heparin, 100 units/mL in a 30 mL multidose vial - Qty of 50 by Medline These items will have a delay in shipment due to regulatory issues. | |
 |
Chemistry and Biology of Heparin and Heparan Sulfate by Hari G. Garg (Editor), Robert J. Linhardt (Editor), Charles A. Hales (Editor) The chemistry, biochemistry and pharmacology of heparin and heparan sulfate have been and continue to be a major scientific undertaking - heparin and its derivative remain important drugs in clinical practice. Chemistry and Biology of Heparin and Heparan Sulfate provides readers with an insight into the chemistry, biology and clinical applications of heparin and heparan sulfate and examines their function in various physiological and pathological conditions. Providing a wealth of useful information, no other tome covers the diversity of topics in the field. Students, doctors, chemists, biochemists, and research scientists will find this book an invaluable source for updating their current knowledge of developments in this area. *... |
| © 2009 BrightSurf.com |